Manchester Capital Management LLC Has $102,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Manchester Capital Management LLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 242 shares of the company’s stock after purchasing an additional 42 shares during the quarter. Manchester Capital Management LLC’s holdings in IDEXX Laboratories were worth $102,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Resona Asset Management Co. Ltd. bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $10,503,000. Russell Investments Group Ltd. boosted its holdings in shares of IDEXX Laboratories by 39.5% during the fourth quarter. Russell Investments Group Ltd. now owns 70,314 shares of the company’s stock worth $29,066,000 after acquiring an additional 19,917 shares during the period. Federated Hermes Inc. boosted its holdings in shares of IDEXX Laboratories by 3.1% during the fourth quarter. Federated Hermes Inc. now owns 57,979 shares of the company’s stock worth $23,971,000 after acquiring an additional 1,725 shares during the period. Cerity Partners LLC grew its position in shares of IDEXX Laboratories by 4.3% in the fourth quarter. Cerity Partners LLC now owns 11,395 shares of the company’s stock valued at $5,073,000 after purchasing an additional 471 shares during the last quarter. Finally, Bell Asset Management Ltd bought a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $4,634,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 27.5%

Shares of IDEXX Laboratories stock opened at $682.78 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The company has a market capitalization of $54.91 billion, a price-to-earnings ratio of 63.10, a PEG ratio of 3.81 and a beta of 1.49. The firm’s 50-day moving average price is $534.93 and its two-hundred day moving average price is $473.95.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.44 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the company a “hold” rating in a research note on Wednesday, July 2nd. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research report on Monday, May 5th. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $570.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.